Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

NCT02869802 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT02869802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02869802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
Lead sponsor
British Columbia Cancer Agency
Phase
Observational
Overall status
Recruiting
Start date
October 6, 2016
Completion date
December 31, 2028
Enrollment
190 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, pancreatic cancer